NASDAQ:ALNA Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free ALNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.02▼$0.1652-Week Range N/AVolume96,558 shsAverage Volume15.69 million shsMarket Capitalization$37,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisInsider TradesSocial MediaStock AnalysisInsider TradesSocial Media Get Allena Pharmaceuticals alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Allena Pharmaceuticals Stock (NASDAQ:ALNA)Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Read More Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. ALNA Stock News HeadlinesNovember 5, 2023 | morningstar.comAllena Pharmaceuticals Inc ALNAQ Stock QuoteAugust 28, 2023 | investing.comAllena Pharmaceuticals Inc (ALNAQ)May 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 6, 2023 | bizjournals.comSan Francisco Pharmaceuticals NewsSeptember 29, 2022 | reuters.comALNA.OSeptember 6, 2022 | wsj.comFirm Retention Summary: Allena Pharmaceuticals Inc.September 6, 2022 | finance.yahoo.comAllena Pharmaceuticals Shares Fall After Filing For BankruptcyAugust 11, 2022 | finance.yahoo.comAllena Pharma Needs To Raise Capital To Continue As A Going ConcernMay 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.August 11, 2022 | marketwatch.comAllena Pharmaceuticals Warns of Imminent Funding Need >ALNAJuly 19, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney DiseaseJuly 12, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitJuly 12, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitJuly 5, 2022 | apnews.comAllena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitJuly 5, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitJuly 1, 2022 | uk.investing.comWhy Shares Of Allena Pharmaceuticals Are Skyrocketing TodayJune 29, 2022 | investorplace.comALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%May 16, 2022 | msn.comShort Volatility Alert: Allena PharmaceuticalsMay 12, 2022 | investorplace.comALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%May 12, 2022 | seekingalpha.comNano cap stock Allena surges on heavy volumeMay 4, 2022 | seekingalpha.comAllena Pharmaceuticals $2.8M direct offeringMay 4, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces $2.8 Million Registered Direct OfferingMarch 22, 2022 | seekingalpha.comAllena downgraded to Neutral at B. Riley citing the end to lead clinical programMarch 21, 2022 | finance.yahoo.comWhy Are Allena Pharma Shares Plunging TodayMarch 21, 2022 | seekingalpha.comAllena extends losses on plans to end trial for lead asset and financial concernsMarch 1, 2022 | finance.yahoo.comAllena Pharmaceuticals, Inc. (ALNA)January 29, 2022 | fool.comAllena Pharmaceuticals, Inc.(ALNA)See More Headlines Receive ALNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2022Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALNA CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone(617) 467-4577Fax617-916-1871Employees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-287.46% Return on Assets-146.58% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / BookN/AMiscellaneous Outstanding Shares122,083,000Free Float117,566,000Market Cap$37,000.00 OptionableNot Optionable Beta1.13 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Alexey L. Margolin Ph.D. (Age 69)Co-Founder & Chairman Comp: $70kDr. Louis Brenner M.B.A. (Age 52)M.D., Pres, CEO & Director Comp: $576.86kDr. Richard D. Katz (Age 58)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $400.67kMr. Robert Gallotto (Age 57)Co-Founder & Strategic Adviser Mr. Geoffrey A. Swire (Age 49)Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer Mr. Hugh WightSr. VP of Technical OperationsDr. Alicja Januszewicz Ph.D.VP of People & CultureDr. David J. Clark (Age 57)Chief Medical Officer More ExecutivesKey CompetitorsIgnyte AcquisitionNASDAQ:IGNYStatera BiopharmaNASDAQ:STABBruush Oral CareNASDAQ:BRSHScopus BioPharmaNASDAQ:SCPSHumanigenNASDAQ:HGENView All Competitors ALNA Stock Analysis - Frequently Asked Questions How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) posted its quarterly earnings data on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO? 1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN). When did Allena Pharmaceuticals IPO? Allena Pharmaceuticals (ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:ALNA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.